Original Article

You have full text access to this OnlineOpen article

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

  1. Akinori Kasahara1,
  2. Norio Hayashi M.D.1,*,
  3. Kiyoshi Mochizuki1,
  4. Masahide Takayanagi1,
  5. Kentaro Yoshioka1,
  6. Shinichi Kakumu2,
  7. Akihiro Iijima1,
  8. Akihiko Urushihara1,
  9. Kendo Kiyosawa3,
  10. Michiari Okuda1,
  11. Keisuke Hino1,
  12. Kiwamu Okita4

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510270529

Issue

Hepatology

Hepatology

Volume 27, Issue 5, pages 1394–1402, May 1998

Additional Information

How to Cite

Kasahara, A., Hayashi, N., Mochizuki, K., Takayanagi, M., Yoshioka, K., Kakumu, S., Iijima, A., Urushihara, A., Kiyosawa, K., Okuda, M., Hino, K. and Okita, K. (1998), Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology, 27: 1394–1402. doi: 10.1002/hep.510270529

Author Information

  1. 1

    First Department of Medicine, Osaka University School of Medicine, Osaka, Japan

  2. 2

    Third Department of Medicine, Nagoya University School of Medicine, Nagoya, Japan

  3. 3

    Second Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan

  4. 4

    First Department of Medicine, Yamaguchi University School of Medicine, Ube, Japan

*First Department of Medicine, Osaka University School of Medicine, 2-2, Yamadaoka, Suita City, Osaka 565-0871, Japan. Fax: 81-6-879-3639

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003
  3. Manuscript Accepted: 2 DEC 1997
  4. Manuscript Received: 22 JUL 1997

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (112K)

REFERENCES

  • 1
    Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14:969–974.MEDLINE
    Direct Link:
  • 2
    Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nagano Y, Furuta S et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma. Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671–675.MEDLINE
    Direct Link:
  • 3
    Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C. A prospective study of 251 patients. Hepatology 1995; 21:650–655.MEDLINE
    Direct Link:
  • 4
    Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18:47–53.MEDLINE
    Direct Link:
  • 5
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463–472.MEDLINE
  • 6
    Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, Kobayashi K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12:680–687.MEDLINE
    Direct Link:
  • 7
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Rerrilo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. N Engl J Med 1989; 321:1501–1506.MEDLINE
  • 8
    Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double blind placebo-controlled trial. N Engl J Med 1989; 321:1506–1510.MEDLINE
  • 9
    Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, Fusamoto H, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α. Hepatology 1992; 15:37–41.MEDLINE
    Direct Link:
  • 10
    Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104:877–883.MEDLINE
  • 11
    Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21:291–297.MEDLINE
    Direct Link:
  • 12
    Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna Y, Naito M, et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 1995; 22:135–142.MEDLINE
  • 13
    Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 1992; 15:1013–1016.MEDLINE
    Direct Link:
  • 14
    Hagiwara H, Hayashi N, Kasahara A, Oshita M, Katayama K, Naito M, Masuzawa M, et al. Long-term biochemical and virological response to natural interferon-α in patients with chronic hepatitis C. Dig Dis Sci 1996; 41:1001–1007.MEDLINE
  • 15
    Hagiwara H, Hayashi N, Kasahara A, Oshita M, Katayama K, Kato M, Masuzawa M, et al. Treatment with recombinant interferon-α2a for patients with chronic hepatitis C: predictive factors for biochemical and virologic response. Scand J Gastroenterol 1996; 31:1021–1026.MEDLINE
  • 16
    Kuzushita N, Hayashi N, Katayama K, Kanto T, Oshita M, Hagiwara H, Kasahara A, et al. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 1997; 32:169–174.MEDLINE
  • 17
    Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, Masuzawa M, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997; 26:574–583.MEDLINE
  • 18
    Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, Katayama K, et al. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol 1995; 22:457–463.MEDLINE
  • 19
    Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673–679.MEDLINE
  • 20
    Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, Ohta N, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19:1347–1353.MEDLINE
    Direct Link:
  • 21
    Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19:1321–1324.MEDLINE
    Direct Link:
  • 22
    Lau YN, Davis G, Kniffen J, Qian K-P, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341:1501–1504.MEDLINE
  • 23
    Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997; 113:558–566.MEDLINE
  • 24
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431–435.MEDLINE
    Direct Link:
  • 25
    Yokosuka O, Omata M, Imazeki F, Ito Y, Okuda K. Hepatitis B virus RNA transcripts and DNA in chronic liver disease. N Engl J Med 1986; 315:1187–1192.MEDLINE
  • 26
    Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, Kamada T. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17:545–550.MEDLINE
    Direct Link:
  • 27
    Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994; 106:686–690.MEDLINE
  • 28
    Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051–1055.MEDLINE
  • 29
    Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, Di Napoli A, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. Hepatology 1993; 18:1300–1305.MEDLINE
    Direct Link:
  • 30
    Castillo I, Bartolome J, Navas S, Gonzalez S, Herrero M, Carreno V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994; 19:1342–1346.MEDLINE
    Direct Link:
  • 31
    Mazzelia G, Accogli E, Sottili S, Festi G, Orsini M, Salzetta A, Novelli V. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24:141–147.MEDLINE
  • 32
    Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797–1801.MEDLINE
  • 33
    Lai CL, Lau JYN, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, et al. Recombinant IFN-α in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17:389–394.MEDLINE
    Direct Link:
  • 34
    Tatsumi T, Takehara T, Katayama K, Mochizuki K, Yamamoto M, Kanto T, Sasaki Y, et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology 1997; 25:1108–1114.MEDLINE
    Direct Link:
  • 35
    Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16:293–299.MEDLINE
    Direct Link:
  • 36
    Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39:977–982.MEDLINE
  • 37
    Mita E, Hayashi N, Kanazawa Y, Hagiwara H, Ueda K, Kasahara A, Fusamoto H, et al. Hepatitis C virus genotype and RNA titer in the progression of type C chronic liver disease. J Hepatol 1994; 21:468–473.MEDLINE
  • 38
    Takada N, Takase S, Enomoto N, Takada A, Date T. Clinical backgrounds of patients having different types of hepatitis C virus genomes. J Hepatol 1992; 14:35–40.MEDLINE
  • 39
    Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21:285–290.MEDLINE
  • 40
    Pozzato G, Kaneko S, Moretti M, Croce LS, Franzin F, Unoura M, Bercich L, et al. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994; 43:291–296.MEDLINE
    Direct Link:
  • 41
    Noubaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122:161–168.MEDLINE
  • 42
    Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996; 111:119–205.
  • 43
    Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis viruses. Hepatology 1996; 23:695–699.MEDLINE
    Direct Link:
  • 44
    Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, Reynes M. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108:1088–1096.MEDLINE
  • 45
    Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa T, Takayanagi M. Hepatitis C virus genotypes are not responsible for development of serious liver disease. Dig Dis Sci 1994; 39:234–239.MEDLINE
  • 46
    Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C-related cirrhosis. Hepatology 1997; 25:211–215.MEDLINE
    Direct Link:
Get PDF (112K)